Voluntary licensing of long‐acting HIV prevention and treatment regimens: using a proven collaboration‐ and competition‐based mechanism to rapidly expand at‐scale, sustainable, quality‐assured and affordable supplies in LMICs

INTRODUCTION: Emerging long‐acting (LA) prevention and treatment medicines, technologies and regimens could be game‐changing for the HIV response, helping reach the ambitious goal of halting the epidemic by 2030. To attain this goal, the rapid expansion of at‐scale, sustainable, quality‐assured, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaayeb, Lobna, Das, Aditi, James, Ike, Murthy, Rajesh, Nobre, Sandra, Burrone, Esteban, Morin, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339000/
https://www.ncbi.nlm.nih.gov/pubmed/37439078
http://dx.doi.org/10.1002/jia2.26092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339000/
https://www.ncbi.nlm.nih.gov/pubmed/37439078
http://dx.doi.org/10.1002/jia2.26092

Ejemplares similares